Alector reports inducement grants under nasdaq listing rule 5635(c)(4)

South san francisco, calif., dec. 08, 2022 (globe newswire) -- alector, inc. (nasdaq: alec), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that on december 6, 2022, the compensation committee of alector's board of directors granted 8 (eight)  new employees options to purchase an aggregate of 91,851 shares of the company's common stock and restricted stock units (rsus) for an aggregate of 40,961 shares of the company's common stock. these awards are made under alector's 2022 inducement equity incentive plan (the “plan”).
ALEC Ratings Summary
ALEC Quant Ranking